BNB Plus (BNBX) Maxim Group’s 2024 Healthcare Virtual Summit summary

Strategic transformation and business focus

• Transitioned to a pure-play biotech, focusing on linear DNA for therapeutics and manufacturing applications.

• Linea Rx segment centers on enzymatic manufacture of synthetic DNA for genetic medicines, with GMP production milestone imminent.

• Shift driven by industry demand for alternatives to plasmid DNA, especially after mRNA COVID-19 vaccine success.

• Engaged with biotech, pharma, and CDMOs for evaluation and supply of Linea IVT templates.

• DNA production for biotherapeutic applications is now the primary business.

Technology platforms and competitive advantages

• Developed Linear DNA (cell-free, scalable) and Linea IVT platforms, enabling faster, higher-quality RNA production.

• Acquisition of Spindle Biotech and proprietary RNAP enzyme increased output, reduced double-stranded RNA, and expanded total addressable market sixfold.

• Modified RNAP enzyme improves efficiency, fidelity, and supports self-amplifying RNA template development.

• Eliminates need for master cell banks and downstream filtration, simplifying regulatory and production workflows.

• Proprietary polymerase nearly eliminates double-stranded RNA contaminants, addressing key safety and quality concerns.

Market opportunity and customer impact

• Linear DNA and IVT platforms enable rapid turnaround: sequence to template in 21 days, aiming for 14 days, versus 6–8 months for plasmid-based methods.

• Speed and quality, rather than cost savings, are primary customer drivers; significant impact on personalized medicine and rare disease treatments.

• Large pharma aligning with similar technologies, validating the market direction and creating partnership opportunities.

• Technology is "sticky"—once adopted in drug development, it becomes embedded in protocols, supporting recurring revenue.

• Supporting clinical trials for CAR T therapies using the linear platform.